NCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
40 trialsNCT07426757 2026-04-07
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pfizer
Phase 1 Not yet recruiting
NCT07340190 2026-04-02
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Novartis
Phase 1 Not yet recruiting
NCT05351697 2026-03-17
BR105-I
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT03233139 2026-02-12
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT06038058 2025-12-30
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06937957 2025-11-21
A Study of BR111 in Patients With Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04837196 2025-08-08
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Inc
Phase 1/2 Completed
NCT05987605 2025-02-19
Phase I/II Clinical Study of 1A46 Drug Substance
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04651348 2024-11-20
A Clinical Study of MIL95 in Advanced Malignancies.
Beijing Mabworks Biotech Co., Ltd.
Phase 1 Recruiting
NCT04949191 2024-09-19
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Incyte Corporation
Phase 2 Terminated
NCT05048134 2024-09-19
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT06468098 2024-07-18
A Study of IBI363 in Subjects With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Recruiting
NCT04671875 2024-03-13
A Clinical Study of MIL93 in Solid Tumors.
Beijing Mabworks Biotech Co., Ltd.
Phase 1 Unknown
NCT03907969 2024-02-06
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
AstraZeneca
Phase 1/2 Completed
NCT06206915 2024-01-16
Phase I Study of XZ120 in Malignant Tumors
Shandong New Time Pharmaceutical Co., LTD
Phase 1 Not yet recruiting
NCT03995472 2023-09-28
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04025957 2023-09-28
A Study of SHR-1501 in Patients With Advanced Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05245916 2023-09-05
IBI397 or Combination Therapies in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Withdrawn
NCT04353830 2023-03-01
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04916119 2022-09-16
Study of IBI323 in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT04085185 2022-09-14
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT04831944 2022-08-26
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
Incyte Corporation
Phase 1 Completed
NCT04831996 2022-08-17
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
Incyte Corporation
Phase 1 Completed
NCT03717103 2022-04-07
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05024305 2022-03-09
Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.
Shandong TheraWisdom Biopharma Co., Ltd.
Phase 1 Unknown
NCT03763149 2021-12-06
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03158272 2020-12-21
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed
NCT00426140 2020-12-08
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
Novartis
Phase 1 Completed
NCT04340427 2020-07-01
A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT00651664 2019-03-15
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT00500903 2019-03-14
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT02678260 2018-06-08
Phase I Study of PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Completed
NCT02013804 2017-10-06
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
MedImmune LLC
Phase 1 Completed
NCT02520245 2016-11-07
Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
Regeneron Pharmaceuticals
Phase 1 Withdrawn
NCT00779428 2015-10-12
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
Bristol-Myers Squibb
Phase 2 Completed
NCT00724425 2015-04-15
A Phase 1 Dose Escalation Study of IPI-493
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00652158 2013-09-23
A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00955084 2010-09-24
Maintenance Study on the Long Term Safety of XL999
Symphony Evolution, Inc.
Phase 1 Completed
NCT00083525 2008-01-24
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Heidelberg Pharma AG
Phase 1 Completed